Sumeet Gujral

Sumeet Gujral

Auto-generated profile, based on publicly available information

Sumeet Gujral

Department of Pathology, Tata Memorial Hospital, Mumbai, India

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
RARita Alaggio
Rita Alaggio
CACatalina Amador
Catalina Amador
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
AAAyoma D. Attygalle
Ayoma D. Attygalle
IAIguaracyra Barreto de Oliveira Araujo
Iguaracyra Barreto de Oliveira Araujo
WXWenbin Xiao
Wenbin Xiao
We herein present an overview of the upcoming 5thedition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4thedition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5thedition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

19 July 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
RARita Alaggio
Rita Alaggio
CACatalina Amador
Catalina Amador
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
AAAyoma D. Attygalle
Ayoma D. Attygalle
IAIguaracyra Barreto de Oliveira Araujo
Iguaracyra Barreto de Oliveira Araujo
WXWenbin Xiao
Wenbin Xiao

19 September 2008 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
SGS. Gujral
S. Gujral
YBY. Badrinath
Y. Badrinath
AKA. Kumar
A. Kumar
PSP. G. Subramanian
P. G. Subramanian
GRG. Raje
G. Raje
CNC. N. Nair
C. N. Nair
Background: To analyze the spectrum of various types and subtypes of acute leukemia.Methods: Two thousand five hundred and eleven consecutive new referral cases of acute leukemia (AL) were evaluated based on WHO classification.Results: It included 1,471 cases (58%) of acute lymphoblastic leukemia (ALL), 964 cases (38%) of acute myeloid leukemia (AML), 45 cases (1.8%) of chronic myelogenous leukemia in blast crisis (CMLBC), 37 cases (1.5%) of biphenotypic acute leukemia (BAL), 1 case of Triphenotypic AL, and 2 cases of acute undifferentiated leukemia (AUL). Common subtypes of ALL were B‐cell ALL (76%), which comprised of intermediate stage/CALLA positive (73%), early precursor/proBALL (3%). T‐cell ALL constituted 24% (351 cases) of ALL. Common subtypes of AML included AMLM2 (27%), AMLM5 (15%), AMLM0 (12%), AMLM1 (12%), APML (11%), and AML t(8;21) (9%). CMLBC was commonly of myeloid blast crisis subtype (40 cases).Conclusion: B‐cell ALL was the commonest subtype in children and AML in adults. Overall incidence of AML in adults was low (53% only). CD13 was most sensitive and CD117 most specific for determining myeloid lineage. A minimal primary panel of nine antibodies consisting of three myeloid markers (CD13, CD33, and CD117), B‐cell lymphoid marker (CD19), T‐cell marker (CD7), with CD45, CD10, CD34, and HLADR could assign lineage to 92% of AL. Cytogenetics findings lead to a change in the diagnostic subtype of myeloid malignancy in 38 (1.5%) cases. © 2008 Clinical Cytometry Society

1 January 2009 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SGSumeet Gujral
Sumeet Gujral
SPSunita Narayan Polampalli
Sunita Narayan Polampalli
YBY. Badrinath
Y. Badrinath
AKAshok Kumar
Ashok Kumar
SGSubramanian P. G.
Subramanian P. G.
CNChandralekha Nair
Chandralekha Nair
We evaluated the diagnostic utility of flow cytometry immunophenotyping in bone marrow aspirates and peripheral blood, in the assessment of mature B-cell non-Hodgkin lymphoma (MBNHL). We analyzed 356 cases of MBNHL received for immunophenotyping over a 4 year period. All cases were reviewed, correlated with biopsy specimen (lymph node and splenectomy). Discrepant cases were re-evaluated. Common subtypes included chronic lymphocytic leukemia (CLL) (243 cases, 68.5%), follicular lymphoma (30 cases, 8.5%), mantle cell lymphoma (20 cases, 5.5%), splenic marginal zone lymphoma (18 cases, 5%), hairy cell leukemia (18 cases, 5%). CD5+/CD23+ had a high positive predictive value (PPV) for diagnosing CLL whereas CD5+/CD23- had a high negative predictive value (NPV) for diagnosing mantle-cell lymphoma (MCL). Limited panel of 9 antibodies mainly CD19, CD5, CD23, CD10, FMC7, kappa, lambda, CD3 and CD20 help diagnose more than 92% of cases of MBNHL. Minimal diagnostic panels become important in countries with limited resources.

1 January 2008 in Indian Journal of Pathology and Microbiology
Verified
Journal Article
Open access
PDF file
SGSumeet Gujral
Sumeet Gujral
PSPg Subramanian
Pg Subramanian
NPNikhil Patkar
Nikhil Patkar
YBY Badrinath
Y Badrinath
AKAshok Kumar
Ashok Kumar
ADAmar Dasgupta
Amar Dasgupta
Background: Immunophenotyping of hematolymphoid neoplasms is being done in many laboratories in India. The first national meeting on "Guidelines for Immunophenotyping of Hematolymphoid Neoplasms by Flow Cytometry" was held on 14 March 2008 in Mumbai, India. Aim: To achieve uniformity in the laboratory practice regarding antibody panel selection in diagnosing hematolymphoid neoplasms. Settings and Design: Members of the Inter-Laboratory Comparison Program (ILCP) group in Mumbai prepared a draft regarding immunophenotypic panel selection for acute leukemias (ALs) and chronic lymphoproliferative disorders (CLPDs), which was further circulated among national and international cytometrists, hematopathologists, and oncologists for their written inputs, suggestions, proposed modifications; as well as their indications, if any, of the recommendations not being acceptable. Practice-based questionnaire was circulated among all the participants. Results: Consensus was attained, and the panel recommended the use of a minimal screening panel, followed by a secondary directed panel. The aim of the minimal screening panel would be to provide a diagnosis of all commonly occurring hematolymphoid neoplasms without the need of additional antibodies in most cases. Conclusion: Thus we could attain a consensus for our guidelines in selecting panels for ALs and CLPDs. The guideline is an attempt to formulate a minimal panel for immunophenotyping of hematolymphoid neoplasms. Laboratories are encouraged to add additional antibodies to the above panel to increase the sensitivity; however, they should refrain from immunophenotyping with fewer antibodies. This national guideline hopefully brings about uniformity and comparability in reporting of leukemia and lymphoma and bridges the divide between low-cost reporting and an accurate diagnosis.

1 January 2009 in Indian Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SGS Gujral
S Gujral
SPS Polampalli
S Polampalli
YBY Badrinath
Y Badrinath
AKA Kumar
A Kumar
ACA Chogule
A Chogule
CNCn Nair
Cn Nair
Background : We present a clinico-hematological profile and treatment outcome of Biphenotypic Acute Leukemia (BAL). Aim : Study incidence and subtypes of BAL, correlate with age, morphology, and cytogenetic findings and correlate the clinico-hematological data with the treatment response. St Jude's and the EGIL's criteria have been compared for their diagnostic and clinical relevance. Material and Methods : Diagnosis was based on WHO classification, including clinical details, morphology, cytochemistry, immunophenotyping, and molecular genetics. We included those cases, which fulfilled the European Group for the Immunological Characterization of Acute Leukemia's (EGIL's) scoring system criteria for the diagnosis of BAL, as per recommendation of the WHO classification. Results : There were 32 patients diagnosed with BAL, based on EGIL's criteria. Incidence of BAL was 1.2%. B-Myeloid (14 cases) followed by T-Myeloid BAL (13 cases) were the commonest subtypes. Polymorphous population of blasts (16 cases) was commonly associated with T-Myeloid BAL (10 cases). BCR ABL fusion positivity was a common cytogenetic abnormality (seven cases). Fifteen patients received chemotherapy; eight achieved complete remission (CR) at the end of the induction period. Conclusions : Pediatric BAL and T-B lymphoid BAL have a better prognosis. A comprehensive panel of reagents is required, including cytoplasmic markers; to diagnose BAL. St Jude's criteria is a simple, easy, and cost-effective method to diagnose BAL. The outcome-related prognostic factors include age, HLA-DR, CD34 negativity, and subtype of BAL. BCR-ABL expression is an important prognostic factor, as these cases will be labeled as Chronic myeloid leukemia (CML) in blast crisis with biphenotypic expression and treated accordingly.